Search Result

Results for "

Pd/C

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PD-1/PD-L1 (16) 5-HT Receptor (1) Amino Acid Derivatives (1) AMPK (1) Apoptosis (4) Bcr-Abl (5) Biochemical Assay Reagents (1) c-Fms (1) c-Met/HGFR (1) c-Myc (1) Calcium Channel (2) CDK (1) COMT (1) Drug Intermediate (1) E3 Ligase Ligand-Linker Conjugates (2) EGFR (3) Endogenous Metabolite (1) FGFR (4) FXR (1) HIF/HIF Prolyl-Hydroxylase (1) Histone Acetyltransferase (1) Histone Demethylase (1) Histone Methyltransferase (1) HSP (1) IGF-1R (1) IKZF Family (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Interleukin Related (1) Isotope-Labeled Compounds (1) LDLR (2) Ligands for Target Protein for PROTAC (2) Liposome (1) MAP4K (1) MEK (1) Melatonin Receptor (1) Molecular Glues (1) Monoamine Oxidase (4) PARP (1) PDGFR (2) PI3K (1) Potassium Channel (1) Prostaglandin Receptor (1) PROTAC Linkers (2) PROTACs (2) PTEN (1) Reactive Oxygen Species (ROS) (1) Reference Standards (3) Small Interfering RNA (siRNA) (1) Src (2) STAT (2) TGF-beta/Smad (1) TGF-β Receptor (1) VEGFR (2) α-synuclein (1)
By Research Areas:	Cancer (39) Cardiovascular Disease (4) Infection (2) Inflammation/Immunology (13) Metabolic Disease (4) Neurological Disease (10)
Oligonucleotides:	Cationic Lipids (1) Human Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Bibliothèques de criblage

Peptides

Inhibitory Antibodies

Natural
Products

Protéines recombinantes

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: PD-1/PD-L1

Cat. No.	Nom du produit	Target	Áreas de investigación	Chemical Structure

HY-108730

Avelumab 5+ Cited Publications Anti-Human Pd-L1, Human Antibody; MSB 0010718C; MSB0010718C	PD-1/PD-L1	Inflammation/Immunology Cancer
Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma .

HY-10321

PD173074 Maximum Cited Publications 21 Publications Verification	FGFR VEGFR Apoptosis	Cancer
PD173074 is a potent FGFR1 inhibitor with an IC₅₀ of 25 nM and also inhibits VEGFR2 with an IC₅₀ of 100-200 nM, showing 1000-fold selectivity for FGFR1 over PDGFR and c-Src.

HY-148794

Risvodetinib IkT-148009	c-Met/HGFR Bcr-Abl	Neurological Disease Cancer
Risvodetinib (IkT-148009) is an orally active, selective and brain-penetrant protein tyrosine kinase inhibitor, displaying excellent target efficacy against *c-Abl1, c-Abl2/Arg* with IC₅₀ values of 33 nM, 14 nM, respectively. Risvodetinib suppresses *c-Abl* activation and substantially protects dopaminergic neurons from degeneration in mouse models of both inherited and sporadic Parkinson’s disease (PD), which is promising for research in the field of PD .

HY-124447

BTYNB	IGF-1R c-Myc Apoptosis TGF-beta/Smad	Cancer
BTYNB is a structure-specific nucleic acid binder and IGF2BP1 inhibitor (with an IC₅₀ of 5 μM against hBTYNB). BTYNB disrupts the IGF2BP1-RNA interaction and blocks its binding to oncogenic mRNAs such as c-Myc, MDM2, PD-L1. BTYNB completely blocks the INHBA-Smad2/3 pathway, disrupts the MYCN/IGF2BP1 loop, and thereby induces apoptosis and cell cycle arrest, effectively inhibiting the proliferation and survival of cancer cells. In addition, BTYNB acts as an immune activator and tumor microenvironment modulator, enhances T cell-mediated tumor killing, and produces significant synergistic effects with inhibitors of PD-1, BRD and BIRC5. BTYNB can be used in relevant research on various malignant tumors including ovarian cancer, neuroblastoma, leukemia and melanoma .

HY-100434

PD-161570	FGFR PDGFR EGFR Src TGF-β Receptor	Cardiovascular Disease Cancer
PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC₅₀ of 39.9 nM and a K_i of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC₅₀ values of 310 nM, 240 nM, and 44 nM, respectively. PD-161570 inhibits PDGF-stimulated autophosphorylation and FGF-1 receptor phosphorylation with IC₅₀s of 450 nM and 622 nM, respectively . PD-161570 is also a bone morphogenetic proteins (BMPs) and TGF-β signaling inhibitor .

HY-W590989

GPhos Pd G6 GPhos Pd G6 TES	Drug Intermediate	Others
GPhos Pd G6 (GPhos Pd G6 TES) is a palladium catalyst. GPhos Pd G6 catalyzes the Buchwald-Hartwig amination reaction and promotes C-N bond formation between aryl chlorides and amines. GPhos Pd G6 is a pharmaceutical intermediate used for the synthesis of various active compounds .

HY-N3431

Kaempferol-7-O-rhamnoside	AMPK PD-1/PD-L1 FXR Reactive Oxygen Species (ROS)	Cardiovascular Disease
Kaempferol-7-O-rhamnoside is a *PD-1/PD-L1* inhibitor and farnesoid X receptor (FXR) agonist. Kaempferol-7-O-rhamnoside demonstrates cardioprotective potential targeting the AMPKα1 signaling pathway. Kaempferol-7-O-rhamnoside significantly upregulates the mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Kaempferol-7-O-rhamnoside reverses APAP-induced reduction of glutathione (GSH) content and increase of ROS production in L02 cells. Kaempferol-7-O-rhamnoside has the potential for heart failure .

HY-162275

JMJD1C-IN-1	Histone Demethylase Histone Methyltransferase STAT	Cancer
JMJD1C-IN-1 is an orally active and selective inhibitor of *JMJD1C* (IC₅₀ = 0.59 μM, K_d = 1.96 μM). JMJD1C-IN-1 inhibits the binding of JMJD1C to H3K9me2 peptide substrate in the HTRF assay (IC₅₀ = 1.47 μM). JMJD1C-IN-1 disrupts intratumoral regulatory T (Treg) cell fitness by dual mechanisms: promoting H3K9me2 accumulation to downregulate *PD1* expression and reducing STAT3 demethylation to enhance STAT3 activation. JMJD1C-IN-1 demonstrates dose-dependent antitumor efficacy in multiple mouse tumor models (MCA205 fibrosarcoma, B16-F10 melanoma, LLC lung cancer, Hepa1-6 hepatocellular carcinoma, CT26 colorectal cancer). JMJD1C-IN-1 can be used for the study of tumor immunotherapy by selectively targeting intratumoral Treg cells .

HY-41121

Boc-L-Ala-OH 1 Publications Verification Boc-Ala-OH	Amino Acid Derivatives	Cancer
Boc-L-Ala-OH (Boc-Ala-OH) is a single N-protected amino acid ligand and a protected L-alanine derivative. Boc-L-Ala-OH promotes Pd (II)-catalyzed enantioselective C-H alkenylation and kinetic resolution. Boc-L-Ala-OH serves as a coupling reagent for the synthesis of liver-targeted glycogen phosphorylase inhibitors and P6A metabolites, and also acts as a negative control in synthesis studies of betulinic acid amino acid esters. Boc-L-Ala-OH is applicable to research on epidermoid squamous cell carcinoma .

HY-109567

Gemcabene Pd-72953	LDLR	Metabolic Disease Inflammation/Immunology
Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .

HY-143889

Senexin C	CDK	Cancer
Senexin C is a selective and orally active CDK8/19 inhibitor. Senexin C shows a strong tumor-enrichment pharmacokinetic (PK) profile and tumor-pharmacodynamic (PD) marker responses. Senexin C inhibits the growth of MV4-11 leukemia cells with good tolerability .

HY-145774

PD-1/PD-L1-IN-23	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of *PD-1/PD-L1*. PD-1/PD-L1-IN-23 is an ester proagent of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice .

HY-W004701

Br-C3-methyl ester	PROTAC Linkers	Cancer
Br-C3-methyl ester is a Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183) .

HY-131295

PD0325901-O-C2-dioxolane 2 Publications Verification	MEK Ligands for Target Protein for PROTAC	Cancer
PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader .

HY-112345

PD-089828	FGFR PDGFR EGFR Src	Cancer
PD-089828 is an ATP competitive inhibitor of FGFR-1, PDGFR-β and EGFR (IC₅₀s=0.15, 1.76, and 5.47 µM, respectively) and a noncompetitive inhibitor of *c-Src* tyrosine kinase (IC₅₀=0.18 µM). PD-089828 also inhibits MAPK with an IC₅₀ of 7.1 µM. PD-089828 inhibits PDGF-, EGF- and bFGF-mediated tyrosine kinase receptor autophosphorylation in vitro. PD-089828 has a long-lasting cellular activity .

HY-178360

NP1192	PROTACs Histone Acetyltransferase HIF/HIF Prolyl-Hydroxylase PD-1/PD-L1 PTEN	Metabolic Disease Inflammation/Immunology Cancer
NP1192 is a potent, selective PROTAC NAT10 degrader that depletes NAT10 protein and inhibits ac4C modification in cancer cells. NP1192 demonstrates dual inhibition of hypoxia-driven glycolysis and immunosuppression via NAT10/HIF-1α/PD-L1 axis disruption, achieving superior antitumor efficacy and synergizing with anti-PD-L1 both in vitro and in vivo. NP1192 can be used for ovarian, cervical, and glioblastoma cancer research. (Blue: CRBN ligand (HY-148834); Black: linker; Pink: NAT10 ligand (HY-16706)) .

HY-172930

PVTX-405	Molecular Glues IKZF Family Potassium Channel	Inflammation/Immunology Cancer
PVTX-405 is a selective and oral active IKZF2 molecular glue degrader with a DC₅₀ of 0.7 nM and a D_max of 91%. PVTX-405 enhances degradation efficiency, significantly reduces off-target degradation, and alleviates hERG inhibition with IC₅₀ of 48 µM. PVTX-405 significantly inhibits the growth of MC38 tumors, with greater synergistic anti-cancer efficacy in combination with immune checkpoint therapies (ICTs) (anti-PD1 or anti-LAG3) in the MC38 mouse tumor xenograft model using Crbn ^391V C57BL/6 mice .

HY-P990828

Anti-PD-L1/B7-H1 Antibody (29E.2A3)	PD-1/PD-L1	Infection
Anti-PD-L1/B7-H1 Antibody (29E.2A3) is a kind of mouse IgG2b κ chimeric antibody inhibitor, targeting to human *PD-L1/B7-H1*. Anti-PD-L1/B7-H1 Antibody (29E.2A3) can block the binding of PD-1 to PD-L1. Anti-PD-L1/B7-H1 Antibody (29E.2A3) can be used for the research of infection, such as hepatitis C virus (HCV) .

HY-106136

TIK-301 Pd-6735; LY-156735	Melatonin Receptor 5-HT Receptor	Neurological Disease
TIK-301 (PD-6735) is a chlorinated melatonin derivative and a potent, high-affinity and orally active melatonin MT₁ and MT₂ receptors agonist with K_is of 0.081 nM and 0.042 nM, respectively. TIK-301 is also a 5-HT_2B/5-HT_2C receptors antagonist with antidepressant action. TIK-301 has the potential for sleep disorders and other circadian rhythm disorders treatment .

HY-169859

EP4 receptor antagonist 7	Prostaglandin Receptor Interleukin Related	Inflammation/Immunology Cancer
EP4 receptor antagonist 7 (Compound 14) is an antagonist of the prostaglandin E2 (PGE2) receptor subtype EP4 with an IC₅₀ value of 1.1 nM. EP4 receptor antagonist 7 inhibits PGE2-induced β-arrestin recruitment in HEK293 cells with an IC₅₀ value of 0.9 nM. EP4 receptor antagonist 7 decreases PGE2-induced expression of mRNA encoding IL-4, macrophage mannose receptor 1 (Mrc1), chitinase-like protein 3 (Chil3), chemokine (C-X-C) motif ligand 1 (Cxcl1), triggering receptor expressed on myeloid cells 2 (Trem2), and arginase-1 (Arg1), in RAW 264.7 macrophages. EP4 receptor antagonist 7 combined with an anti-PD-1 antibody inhibits tumor growth and increases infiltration of CD ⁸⁺ T cells into tumors in a CT26 murine colon cancer model .

HY-162343

PD-1/PD-L1-IN-41	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/ PD-L1-in-41 (Compound 5c) is a *PD-L1* and *PD-1* inhibitor with IC₅₀ value of 10.2 nM .

HY-132212

LH1307	PD-1/PD-L1	Inflammation/Immunology Cancer
LH1307 is a C2-symmetric inhibitor of PD-1/PD-L1 protein-protein interactions with a IC₅₀ value of 3.0 μM and can be used in cancer studies .

HY-131184

N-Boc-piperazine-C3-COOH	PROTAC Linkers	Inflammation/Immunology
N-Boc-piperazine-C3-COOH is a PROTAC linker, which refers to the alkyl/ether composition. Boc-N-piperazine-C3-COOH can be used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183) .

HY-N0079

Praeruptorin C 1 Publications Verification	Calcium Channel	Cardiovascular Disease
Praeruptorin C is a main bioactive constituent of Peucedanum praeruptorum (also known as Bai-Hua Qian Hu). Praeruptorin C is a calcium antagonist with pD₂ ^′ value of 5.7 .

HY-P99963

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .

HY-146527

c-ABL-IN-2	Bcr-Abl	Neurological Disease Cancer
c-ABL-IN-2 is a potent inhibitor of *c-Abl*. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-2 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2020260871A1, compound 25) . c-ABL-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-155580

MAO A/HSP90-IN-2	Monoamine Oxidase HSP	Cancer
MAO A/HSP90-IN-2 (compound 4-C) is a dual inhibitor of HSP90and MAO A with the IC₅₀ values of 0.016 and 4.58 μM, respectively. MAO A/HSP90-IN-2 increases HSP70 expression and reduces HER2 and phospho-Akt expression, and decreases IFN-γ induced *PD-L1* expression in GL26 cells. MAO A/HSP90-IN-2 inhibits the growth of Temozolomide (HY-17364) -sensitive and -resistant GBM cells, colon cancer, leukemia, non-small cell lung and other cancers, and has potential to inhibit tumor immune escape ^[1].

HY-P10826

PD-1/PD-L1 inhibitory peptide C8	PD-1/PD-L1	Cancer
PD-1/PD-L1 inhibitory peptide C8 is inhibits *PD-1/PD-L1* interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model .

HY-168081

PD-1/PD-L1-IN-52	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-52 (Compound III-5) is an orally active *PD-1/PD-L1* inhibitor that blocks the interaction between PD-1 and PD-L1, with an IC₅₀ of 109.9 nM. PD-1/PD-L1-IN-52 exhibits antitumor activity in a C57BL/6 mouse xenograft model implanted with human PD-1-expressing MC38 colon cancer cells, with a TGI of 49.6% .

HY-161748

PD-1/PD-L1-IN-46	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-46 (compound (R)-C27 ) is an PD-1/PD-L1 antagonist with IC₅₀ value of 18.66 nM .

HY-163844

PD-1/PD-L1-IN-49	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-49 (compound 1c) is a potent inhibitor of PD-1/PD-L1, with the IC₅₀ of 77 nM. PD-1/PD-L1-IN-49 activates Jurkat T cells, reflecting successful blockade of the PD-1/PD-L1 immune checkpoint .

HY-132223

LH1306	PD-1/PD-L1	Inflammation/Immunology Cancer
LH1306 is a C2-symmetric inhibitor of *PD-₁/PD-L₁* protein-protein interaction (PPI), with an IC₅₀ value of 25 nM. LH1306 can be used in anti-tumor research .

HY-109567A

Gemcabene calcium Pd-72953 calcium	LDLR	Metabolic Disease Inflammation/Immunology
Gemcabene calcium (PD-72953 calcium), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .

HY-10321R

PD173074 (Standard)	Reference Standards FGFR VEGFR Apoptosis	Cancer
PD173074 (Standard) is the analytical standard of PD173074. This product is intended for research and analytical applications. PD173074 is a potent FGFR1 inhibitor with an IC50 of 25 nM and also inhibits VEGFR2 with an IC50 of 100-200 nM, showing 1000-fold selectivity for FGFR1 over PDGFR and c-Src.

HY-131186

Pomalidomide-amido-C3-piperazine-N-Boc	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-amido-C3-piperazine-N-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183) .

HY-169364

2-Methylbiphenyl-oxadiazole-NH-Ph-NH-PEG3-C2-NH-Boc	PD-1/PD-L1	Others
2-Methylbiphenyl-oxadiazole-NH-Ph-NH-PEG3-C2-NH-Boc is the PD-L1 ligand-linker conjugate part of AUTAC PD-L1 degrader-3 (HY-169363). 2-Methylbiphenyl-oxadiazole-NH-Ph-NH-PEG3-C2-NH-Boc can be utilized in AUTAC synthesis .

HY-162303

C175-0062	Monoamine Oxidase	Neurological Disease
C175-0062 is a monoamine oxidase B (MAO-B) inhibitor. C175-0062 can be used for the research of neurodegenerative disorders, including Parkinson's disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS) .

HY-169480

Lipid C2	Liposome	Infection Cancer
Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNP) for mRNA delivery in vivo. LNPs containing Lipid C2 and encapsulating an mRNA reporter selectively accumulate in the liver and spleen but not the heart, lungs, or kidneys in mice. LNP containing Lipid C2 and encapsulating mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), in combination with an anti-programmed cell death protein 1 (PD-1) antibody, decrease tumor volume and reverse T cell exhaustion, as well as increase the percentage of CD3 ⁺CD8 ⁺ central and CD3 ⁺CD8 ⁺ effector memory T cells and decrease the percentage of CD3 ⁺ T cells expressing Pd-1, in the spleen in a CT26 murine EBV-infected colon cancer model .

HY-162644

Antitumor agent-170	PD-1/PD-L1 PARP	Cancer
Antitumor agent-170 (Compound C6) exhibits inhibitory activities against *PD-1/PD-L1* interaction and PARP7, with IC₅₀ of 0.342 μM and 7.05 nM. Antitumor agent-170 exhibits a high affinity to human PD-L1, with a K_i of 9.31 nM. Antitumor agent-170 restores the T cell function and increases IFN-γ secretion. Antitumor agent-170 exhibits antitumor efficacy against melanoma in mouse models and good pharmacokinetic characteristics .

HY-RS10777

PNKD Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PNKD Human Pre-designed siRNA Set A contains three designed siRNAs for PNKD gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNKD Human Pre-designed siRNA Set A PNKD Human Pre-designed siRNA Set A

HY-172874

TDO-IN-2	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
TDO-IN-2 (Compound 5c) is an orally active TDO inhibitor (IC₅₀: 1.25 μM). TDO-IN-2 has antitumor activity in the Hepa1-6 hepatocellular carcinoma allograft mouse model. TDO-IN-2 has synergistic effects with the PD-1/PD-L1 inhibitor BMS-202 (HY-19745) and can be used to study tumor immune tolerance .

HY-176167

mTOR ligand 1-C6-amino	Ligands for Target Protein for PROTAC	Cancer
mTOR ligand 1-C6-amino is a conjugate of a target protein ligand (HY-B0795) and a linker (HY-W008296). mTOR ligand 1-C6-amino can be used to synthesize PROTAC PD-M6 (HY-176166) .

HY-146528

c-ABL-IN-3	Bcr-Abl	Neurological Disease Cancer
c-ABL-IN-3 is a potent inhibitor of *c-Abl*. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-3 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2021048567A1, compound 50) .

HY-146530

c-ABL-IN-4	Bcr-Abl	Neurological Disease Cancer
c-ABL-IN-4 is a potent inhibitor of *c-Abl*. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-4 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2021048567A1, compound 54) .

HY-156102

c-ABL-IN-5	Bcr-Abl	Neurological Disease
c-ABL-IN-5 is a selective c-Abl inhibitor with neuroprotective effects. c-ABL-IN-5 has blood-brain barrier penetrability, metabolic stability and good pharmacokinetic properties. When c-ABL-IN-5 is labeled with [18F] (compound [18F]3), it can be used as a tracer to evaluate disease-modifying efficacy by complementary positron emission tomography (PET). c-ABL-IN-5 can be used in the study of neurodegenerative diseases such as Parkinson's disease (PD) .

HY-130642

(S,R,S)-AHPC-Me-C10-Br	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-Me-C10-Br is a synthesized E3 ligase ligand-linker conjugate. (S,R,S)-AHPC-Me-C10-Br incorporates a VHL E3 ligase linker and MS432 based on the MEK1/2 inhibitor PD0325901 .

HY-N6066R

Praeruptorin E (Standard)	Reference Standards Calcium Channel	Cardiovascular Disease
Praeruptorin E (Standard) is the analytical standard of Praeruptorin E. This product is intended for research and analytical applications. Praeruptorin E is a main bioactive constituent of Peucedanum praeruptorum (also known as Bai-Hua Qian Hu). Praeruptorin C is a calcium antagonist with pD2′ value of 5.2 .

HY-160002

MAO-B-IN-27	Monoamine Oxidase	Neurological Disease
MAO-B-IN-27 (Compound 12c) is a monoamine oxidase B (MAO-B) inhibitor. MAO-B-IN-27 has potent and selective MAO-B inhibitory effect for hMAO-B with an IC₅₀ values of 8.9 nM. MAO-B-IN-27 can be used for the research of parkinson's disease (PD) .

HY-149509

α-Synuclein inhibitor 9	α-synuclein	Neurological Disease
α-Synuclein inhibitor 9 (Compound 20C) is an α-Synuclein inhibitor. α-Synuclein inhibitor 9 binds to cavities in mature α-synuclein fibrils and reduces the β-sheet structure. α-Synuclein inhibitor 9 inhibits A53T α-Syn aggregation. α-Synuclein inhibitor 9 has neuroprotective effect, improves brain functional connection and relieves motor dysfunction.α-Synuclein inhibitor 9 can be used for Parkinson’s disease (PD) research. .

HY-162760

COMT-IN-1	COMT Monoamine Oxidase	Neurological Disease
COMT-IN-1 (compound C12), a nitrophenolic analogue, is an orally active dopamine metabolic enzyme catechol-O-methyltransferase (COMT) inhibitor with IC₅₀s of 0.37 μM, 95.58 μM and 58.82 μM for COMT, MAO-A and MAO-B, respectively. COMT-IN-1 exhibits chelation with a variety of metal ions. COMT-IN-1 exhibits good BBB permeability. COMT-IN-1 improves dopamine levels and ameliorates MPTP (HY-15608)-induced Parkinson's disease (PD) symptoms in mice .

Cat. No.	Nom du produit

HY-L188

Anti-Brain Cancer Compound Library

2,074 compounds

Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets.

MCE designs a unique collection of 2,074 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.

HY-L010

MAPK Compound Library

1,081 compounds

MAPK families play an important role in complex cellular programs like proliferation, differentiation, development, transformation, and apoptosis. In mammalian cells, four MAPK families have been clearly characterized: ERK1/2, C-Jun N-terminal kinse/stress-activated protein kinase (JNK/SAPK) , p38 kinase and ERK5. They respond to different signals. Each MAPK-related cascade consists of three enzymes that are activated in series: a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAP kinase (MAPK). MAPK signaling pathways has been implicated in the development of many human diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and various types of cancers.

MCE designs a unique collection of 1,081 MAPK signaling pathway inhibitors that act as a useful tool for MAPK-related drug screening and disease research.

Cat. No.	Nom du produit	Target	Research Area

HY-41121

Boc-L-Ala-OH 1 Publications Verification Boc-Ala-OH	Amino Acid Derivatives	Cancer
Boc-L-Ala-OH (Boc-Ala-OH) is a single N-protected amino acid ligand and a protected L-alanine derivative. Boc-L-Ala-OH promotes Pd (II)-catalyzed enantioselective C-H alkenylation and kinetic resolution. Boc-L-Ala-OH serves as a coupling reagent for the synthesis of liver-targeted glycogen phosphorylase inhibitors and P6A metabolites, and also acts as a negative control in synthesis studies of betulinic acid amino acid esters. Boc-L-Ala-OH is applicable to research on epidermoid squamous cell carcinoma .

HY-P10826

PD-1/PD-L1 inhibitory peptide C8	PD-1/PD-L1	Cancer
PD-1/PD-L1 inhibitory peptide C8 is inhibits *PD-1/PD-L1* interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model .

Cat. No.	Nom du produit	Target	Research Area	Image

HY-108730

Avelumab 5+ Cited Publications Anti-Human Pd-L1, Human Antibody; MSB 0010718C; MSB0010718C	PD-1/PD-L1	Inflammation/Immunology Cancer
Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma .

HY-P990828

Anti-PD-L1/B7-H1 Antibody (29E.2A3)	PD-1/PD-L1	Infection
Anti-PD-L1/B7-H1 Antibody (29E.2A3) is a kind of mouse IgG2b κ chimeric antibody inhibitor, targeting to human *PD-L1/B7-H1*. Anti-PD-L1/B7-H1 Antibody (29E.2A3) can block the binding of PD-1 to PD-L1. Anti-PD-L1/B7-H1 Antibody (29E.2A3) can be used for the research of infection, such as hepatitis C virus (HCV) .

HY-P99963

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .

Cat. No.	Nom du produit	Category	Target	Chemical Structure

HY-N3431

Kaempferol-7-O-rhamnoside	Flavonols Flavonoids other families Classification of Application Fields Phenols Polyphenols Metabolic Disease Chimonanthus nitens Oliv. Plants Disease Research Fields Source Classification Calycanthaceae	AMPK PD-1/PD-L1 FXR Reactive Oxygen Species (ROS)
Kaempferol-7-O-rhamnoside is a *PD-1/PD-L1* inhibitor and farnesoid X receptor (FXR) agonist. Kaempferol-7-O-rhamnoside demonstrates cardioprotective potential targeting the AMPKα1 signaling pathway. Kaempferol-7-O-rhamnoside significantly upregulates the mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Kaempferol-7-O-rhamnoside reverses APAP-induced reduction of glutathione (GSH) content and increase of ROS production in L02 cells. Kaempferol-7-O-rhamnoside has the potential for heart failure .

HY-N0079

Praeruptorin C 1 Publications Verification	Cardiovascular Disease Chrysanthemum × morifolium (Ramat.) Hemsl. Classification of Application Fields Coumarins Phenylpropanoids Plants Umbelliferae Disease Research Fields Source Classification	Calcium Channel
Praeruptorin C is a main bioactive constituent of Peucedanum praeruptorum (also known as Bai-Hua Qian Hu). Praeruptorin C is a calcium antagonist with pD₂ ^′ value of 5.7 .

HY-N6066R

Praeruptorin E (Standard)	Structural Classification Coumarins Salvia hypargeia Fisch. & C.A.Mey. Phenylpropanoids Umbelliferae Plants Source Classification	Reference Standards Calcium Channel
Praeruptorin E (Standard) is the analytical standard of Praeruptorin E. This product is intended for research and analytical applications. Praeruptorin E is a main bioactive constituent of Peucedanum praeruptorum (also known as Bai-Hua Qian Hu). Praeruptorin C is a calcium antagonist with pD2′ value of 5.2 .

Species:	Human (9) Mouse (1) Cynomolgus (2) Canine (2)
Tag:	His (11) Avi (4) Fc (3)
Source:	HEK293 (13) CHO (1)

Cat. No.	Compare	Nom du produit	Species	Source	Image

HY-P70799

	PD-1 Protein, Human (C93S, HEK293, His) Programmed cell death protein 1; PdCD1; Pd-1; hPd-1; CD279	Human	HEK293
	PD-1 protein is an inhibitory receptor on T cells that maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It blocks T cell activation by binding to CD3-TCR and recruiting PTPN11/SHP-2 to dephosphorylate key signaling molecules. PD-1 Protein, Human (C93S, HEK293, His) is the recombinant human-derived PD-1 protein, expressed by HEK293 , with C-6*His labeled tag and C93S mutation.

HY-P700710

	ENPP-3 Protein, Canine (HEK293, His) E-NPP 3; NPP3; Pd-Ibeta; NPPase; ENPP3; PdNP3; CD203c; B10; gp130RB13-6; Pd-Iβ	Canine	HEK293
	ENPP-3 is a hydrolase that plays a crucial role in regulating the immune response. ENPP-3 plays an important role in tumor development and invasion. The hypomethylation of the ENPP-3 promoter region is involved in the occurrence and progression of ovarian endometriosis through the AKT/mTOR/4EBP1 signaling pathway. ENPP-3 Protein, Canine (HEK293, His) is the recombinant canine-derived ENPP-3 protein, expressed by HEK293 , with N-His labeled tag.

HY-P78705

	ENPP-3 Protein, Mouse (HEK293, His) ENPP3; CD203c; NPP3; E-NPP3; Pd-Ibeta; NPPase; PdNP3	Mouse	HEK293
	ENPP-3 is a hydrolase that metabolizes extracellular nucleotides (ATP, GTP, UTP, CTP), which is critical for immune regulation of inflammation and chronic allergic reactions. By eliminating extracellular ATP, ENPP-3 inhibits basophil and mast cell activation and suppresses the release of inflammatory cytokines. ENPP-3 Protein, Mouse (HEK293, His) is the recombinant mouse-derived ENPP-3 protein, expressed by HEK293 , with N-10*His labeled tag.

HY-P73342A

	PD-1 Protein, Canine (HEK293, C-His) CD279; hPd-1; PdCD1; Programmed cell death 1; SLEB2	Canine	HEK293
	Programmed cell death protein 1 (Pdcd1) is an immune-inhibitory receptor which delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2, playing a critical role in induction and maintenance of immune tolerance to self. Pdcd1plays a role in anti-tumor immunity and is involved in safeguarding against autoimmunity, but Pdcd1-mediated inhibitory pathway is also exploited by tumors to attenuate anti-tumor immunity. PD-1 Protein, Canine (HEK293, C-His) is the recombinant canine-derived PD-1, expressed by HEK293, with C-6*His labeled tag.

HY-P77879

	VISTA/B7-H5 Protein, Human (HEK293, Fc) B7H5; B7-H5; VISTA; VSIR ; Pd1H; Pd-1H; 4632428N05Rik; C10orf54; Dies1; Gi24; PP2135; SISP1	Human	HEK293
	VISTA/B7-H5 protein, an immunoregulatory receptor, inhibits T-cell response and may regulate embryonic stem cell differentiation by inhibiting BMP4 signaling. It also stimulates MMP14-mediated MMP2 activation, suggesting a role in matrix metalloproteinase processes. These roles highlight the significance of VISTA/B7-H5 in immune regulation, embryonic development, and extracellular matrix dynamics. VISTA/B7-H5 Protein, Human (HEK293, Fc) is the recombinant human-derived VISTA/B7-H5 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P700894

	PD-L2 Protein, Cynomolgus (HEK293, C-His) PdL2; Pd-L2; Butyrophilin B7-DC; CD273, PdCD1 ligand 2; PdCD1L2; PdCD1LG2; B7DC; bA574F11.2; Btdc	Cynomolgus	HEK293
	PD-L2 Protein is an immune checkpoint receptor ligand that binds to PD-1 to activate pathways that inhibit TCR/ BCR-mediated immune cell activation. PDCD1LG2 can inhibit T-cell proliferation and inflammatory cytokine production. The expression of PDCD1LG2 on mouse tumor cells inhibits cytotoxic T-cell-mediated immune responses and can be used as a biomarker or prognostic indicator. PD-L2 Protein, Cynomolgus (HEK293, C-His) is the recombinant cynomolgus-derived PD-L2 protein, expressed by HEK293 , with C-His labeled tag.

HY-P700410

	ENPP-3 Protein, Human (HEK293, His) E-NPP 3; NPP3; Pd-Ibeta; NPPase; ENPP3; PdNP3; CD203c; B10; gp130RB13-6	Human	HEK293
	ENPP3 is a hydrolase that metabolizes extracellular nucleotides, including ATP, GTP, UTP, and CTP, and plays a key role in immune regulation. It modulates mast cell and basophil responses during inflammation and chronic allergic phases by eliminating extracellular ATP, a trigger for inflammatory cytokine release. ENPP-3 Protein, Human (HEK293, His) is the recombinant human-derived ENPP3 protein, expressed by HEK293 , with C-10*His labeled tag.

HY-P700438

	ENPP-3 Protein, Cynomolgus (HEK293, His) E-NPP 3; NPP3; Pd-Ibeta; NPPase; ENPP3; PdNP3; CD203c; B10; gp130RB13-6	Cynomolgus	HEK293
	ENPP3 is a hydrolase that metabolizes extracellular nucleotides, including ATP, GTP, UTP, and CTP, and plays a key role in immune regulation. It modulates mast cell and basophil responses during inflammation and chronic allergic phases by eliminating extracellular ATP, a trigger for inflammatory cytokine release. ENPP-3 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived ENPP3 protein, expressed by HEK293 , with N-10*His labeled tag.

HY-P704579

	ENPP-3 Protein, Human (HEK293, hFc) E-NPP 3; NPP3; Pd-Ibeta; NPPase; ENPP3; PdNP3; CD203c; B10; gp130RB13-6	Human	HEK293
	ENPP3 is a hydrolase that metabolizes extracellular nucleotides, including ATP, GTP, UTP, and CTP, and plays a key role in immune regulation. It modulates mast cell and basophil responses during inflammation and chronic allergic phases by eliminating extracellular ATP, a trigger for inflammatory cytokine release. ENPP-3 Protein, Human (HEK293, hFc) is the recombinant human-derived ENPP-3 protein, expressed by HEK293, with N-hFc labeled tag.

HY-P705017

	ENPP-3 Protein, Human (Biotinylated, CHO, Fc-Avi) E-NPP 3; NPP3; Pd-Ibeta; NPPase; ENPP3; PdNP3; CD203c; B10; gp130RB13-6	Human	CHO

HY-P77925

	ENPP-3 Protein, Human (Biotinylated, HEK293, His-Avi) E-NPP 3; NPP3; Pd-Ibeta; NPPase; ENPP3; PdNP3; CD203c; B10; gp130RB13-6	Human	HEK293
	ENPP3 is a hydrolase that metabolizes extracellular nucleotides, including ATP, GTP, UTP, and CTP, and plays a key role in immune regulation. It modulates mast cell and basophil responses during inflammation and chronic allergic phases by eliminating extracellular ATP, a trigger for inflammatory cytokine release. ENPP-3 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived ENPP-3 protein, expressed by HEK293 , with N-His, N-Avi labeled tag.

HY-P77928

	ENPP-3 Protein, Human (318a.a, HEK293, His) E-NPP 3; NPP3; Pd-Ibeta; NPPase; ENPP3; PdNP3; CD203c; B10; gp130RB13-6	Human	HEK293
	ENPP3 is a hydrolase that metabolizes extracellular nucleotides, including ATP, GTP, UTP, and CTP, and plays a key role in immune regulation. It modulates mast cell and basophil responses during inflammation and chronic allergic phases by eliminating extracellular ATP, a trigger for inflammatory cytokine release. ENPP-3 Protein, Human (318a.a, HEK293, His) is the recombinant human-derived ENPP-3 protein, expressed by HEK293 , with N-His labeled tag.

HY-P77926

	ENPP-3 Protein, Human (110a.a, HEK293, His-Avi) E-NPP 3; NPP3; Pd-Ibeta; NPPase; ENPP3; PdNP3; CD203c; B10; gp130RB13-6	Human	HEK293
	ENPP3 is a hydrolase that metabolizes extracellular nucleotides, including ATP, GTP, UTP, and CTP, and plays a key role in immune regulation. It modulates mast cell and basophil responses during inflammation and chronic allergic phases by eliminating extracellular ATP, a trigger for inflammatory cytokine release. ENPP-3 Protein, Human (110a.a, HEK293, His-Avi) is the recombinant human-derived ENPP-3 protein, expressed by HEK293 , with N-His, N-Avi labeled tag.

HY-P77927

	ENPP-3 Protein, Human (Biotinylated, 110a.a, HEK293, His-Avi) E-NPP 3; NPP3; Pd-Ibeta; NPPase; ENPP3; PdNP3; CD203c; B10; gp130RB13-6	Human	HEK293
	ENPP3 is a hydrolase that metabolizes extracellular nucleotides, including ATP, GTP, UTP, and CTP, and plays a key role in immune regulation. It modulates mast cell and basophil responses during inflammation and chronic allergic phases by eliminating extracellular ATP, a trigger for inflammatory cytokine release. ENPP-3 Protein, Human (Biotinylated, 110a.a, HEK293, His-Avi) is the recombinant human-derived ENPP-3 protein, expressed by HEK293 , with N-His, N-Avi labeled tag.

Compare Products


Products	En stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / En stock - + Ajouter au chariot Obtenir un devis

Cat. No.	Nom du produit	Chemical Structure

HY-176344S

PD1, Arg-13C6,15N4, Lys-13C6,15N2
PD1, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled PD1.

Host:	Mouse (2)
Reactivity:	Human (2)
Application:	IHC-P (2) FC (2) ELISA (2)
Isotype:	IgG1 (2)
Conjugation:	Non-conjugated (2) Biotin (3)
Clonality:	Monoclonal Antibody (1)
Modification:	Unmodified (1)

Cat. No.	Compare	Nom du produit	Application	Reactivity	Image

HY-P83803

	CD203C Antibody (YA3500) ENPP3; B10; NPP3; PdNP3; Pd-IBETA	IHC-P, FC, ELISA	Human
	CD203C Antibody (YA3500) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD203C.

HY-P83803A

	CD203C Antibody (YA3500)(PBS only) ENPP3; B10; NPP3; PdNP3; Pd-IBETA	IHC-P, FC, ELISA	Human
	CD203C Antibody (YA3500) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD203C.